News
March 25, 2024
This latest patent registration provides a pathway to commercial agreements in Canada with high economic potential for CureLab Oncology; separately, CureLab Oncology has provided exclusive licensing rights to its sister company, CureLab Veterinary, for use with dogs, cats and horses
March 20, 2024
Researchers say their ability to create Elenagen was only possible because of their opposition to dominant biotech doctrine
February 29, 2024
February 22, 2024
Progression-free survival of patients treated with chemo+ELENAGEN or chemo only.
December 4, 2023
September 29, 2023
Novel DNA vaccine Elenagen, in combination with a proven chemotherapy, demonstrates promising clinical results against one of the deadliest forms of ovarian cancer
September 29, 2023
CureLab Veterinary is aiming to commercialize a biologic that can alter the microenvironment of cancerous tumors in pets. S&P Global senior analyst Sian Lazell spoke to the company about its anti-cancer vaccine candidate and future pipeline targets.
July 16, 2023
India patent registration opens door to commercial agreements in an enormous market with high economic potential for CureLab Oncology
March 3, 2023
Ballantyne is the co-founder and former chief scientific officer of Aldevron, a leading manufacturer of plasmids and other biologicals
November 5, 2022
CureLab Oncology and CureLab Veterinary are looking for interns to work with our FDA/USDA team on regulatory activities